Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug Read more
Boehringer Ingelheim enters global licensing agreement to develop and commercialise antibodies from A*STAR for targetted cancer therapies Read more
US FDA approves second indication for Skyrizi to treat adults with active psoriatic arthritis Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more